V590

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name: V590
DrugBank Accession Number: DB16437
Background: The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO®^1,2,3. By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose⁴. Other features of this vaccine include potential activity with oral administration via a swish-and-swallow protocol⁴. Merck is currently underway to begin Phase I trials for the vaccine through intramuscular administration (NCT04569786).
Type: Biotech
Groups: Investigational
Biologic Classification: Vaccines
Recombinant
Synonyms: Not Available

Indication: Not Available
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings: Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half-life: Not Available
Clearance: Not Available
Adverse Effects: Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs: Not Available

Drug Interactions: This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions: Not Available

General References

Wolf J, Bruno S, Eichberg M, Jannat R, Rudo S, VanRheenen S, Coller BA: Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens. NPJ Vaccines. 2020 Jun 15;5:51. doi: 10.1038/s41541-020-0204-7. eCollection 2020. [Article]
Genetic Engineering & Biotechnology News (GEN): Merck & Co. and IAVI – V590 [Link]
MERCK: IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2 [Link]
The Motley Fool: This Late-to-the-Party Coronavirus Vaccine Maker Could Be the Biggest Winner Over the Long Run [Link]

External Links

Not Available

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Terminated	Prevention	Coronavirus Disease 2019 (COVID‑19)	1

Drug created at January 15, 2021 18:44 / Updated at January 16, 2021 21:46